European Investor
07 May 2026, 20:25
Kenvue Edges Up 1% as Margin Gains and Kimberly-Clark Deal Progress Steady the Ship
Summit, N.J., May 7, 2026 — Shares in Kenvue rose a modest 1% today after the consumer health company reported first quarter results that showed meaningful progress on profitability, even as organic sales growth remained thin and the business continues to operate in the shadow of its pending acquisition by Kimberly-Clark.
Net sales grew 4.5% to start the year, but the headline figure was heavily flattered by a 3.8% foreign currency tailwind. Organic sales growth — the more honest measure of underlying demand — came in at just 0.7%, driven by 1% favorable pricing partially offset by a 0.3% volume decline. For a company anchored in household staples like Tylenol, Neutrogena, and Listerine, that is a modest performance, though management framed it as a second consecutive quarter of organic growth after a difficult stretch.
Where the report genuinely impressed was on margins. Adjusted gross profit margin expanded 80 basis points to 60.8%, and adjusted operating income margin widened a full 420 basis points to 24.0%, reflecting the benefits of supply chain optimization, cost reduction initiatives, and lower SGA spending. Adjusted diluted EPS of $0.32 was up 33% year-over-year, a meaningful improvement driven more by cost discipline than revenue momentum. Free cash flow also nearly doubled to $0.4 billion.
The segment picture was mixed. Skin Health and Beauty was the standout, with 5% organic growth fueled by Neutrogena internationally and strong eCommerce execution. Essential Health added 1.5% organically. Self Care was the drag, with organic sales falling 2.3% as weak cold and flu seasons across major markets weighed on demand, partially offset by share gains in smoking cessation and sequential improvement for Tylenol.
With the Kimberly-Clark acquisition expected to close in the second half of 2026 and all shareholder and U.S. antitrust approvals already secured, Kenvue is not providing forward-looking guidance. The stock's quiet gain reflects a market content to wait for the deal to close rather than reprice the business on its own merits.
Summit, N.J., May 7, 2026 — Shares in Kenvue rose a modest 1% today after the consumer health company reported first quarter results that showed meaningful progress on profitability, even as organic sales growth remained thin and the business continues to operate in the shadow of its pending acquisition by Kimberly-Clark.
Net sales grew 4.5% to start the year, but the headline figure was heavily flattered by a 3.8% foreign currency tailwind. Organic sales growth — the more honest measure of underlying demand — came in at just 0.7%, driven by 1% favorable pricing partially offset by a 0.3% volume decline. For a company anchored in household staples like Tylenol, Neutrogena, and Listerine, that is a modest performance, though management framed it as a second consecutive quarter of organic growth after a difficult stretch.
Where the report genuinely impressed was on margins. Adjusted gross profit margin expanded 80 basis points to 60.8%, and adjusted operating income margin widened a full 420 basis points to 24.0%, reflecting the benefits of supply chain optimization, cost reduction initiatives, and lower SGA spending. Adjusted diluted EPS of $0.32 was up 33% year-over-year, a meaningful improvement driven more by cost discipline than revenue momentum. Free cash flow also nearly doubled to $0.4 billion.
The segment picture was mixed. Skin Health and Beauty was the standout, with 5% organic growth fueled by Neutrogena internationally and strong eCommerce execution. Essential Health added 1.5% organically. Self Care was the drag, with organic sales falling 2.3% as weak cold and flu seasons across major markets weighed on demand, partially offset by share gains in smoking cessation and sequential improvement for Tylenol.
With the Kimberly-Clark acquisition expected to close in the second half of 2026 and all shareholder and U.S. antitrust approvals already secured, Kenvue is not providing forward-looking guidance. The stock's quiet gain reflects a market content to wait for the deal to close rather than reprice the business on its own merits.